Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Treasury Shares (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Treasury Shares for 8 consecutive years, with $421397.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Treasury Shares fell 33.33% year-over-year to $421397.0, compared with a TTM value of $421397.0 through Sep 2025, down 33.33%, and an annual FY2024 reading of $632100.0, changed N/A over the prior year.
  • Treasury Shares was $421397.0 for Q3 2025 at Avalo Therapeutics, roughly flat from $421397.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $632100.0 in Q3 2024 and bottomed at $11250.0 in Q4 2021.
  • Average Treasury Shares over 4 years is $286255.6, with a median of $288615.0 recorded in 2021.
  • The sharpest move saw Treasury Shares plummeted 92.78% in 2021, then tumbled 33.33% in 2025.
  • Year by year, Treasury Shares stood at $11250.0 in 2021, then changed by 0.0% to $11250.0 in 2022, then skyrocketed by 5518.67% to $632100.0 in 2024, then crashed by 33.33% to $421397.0 in 2025.
  • Business Quant data shows Treasury Shares for AVTX at $421397.0 in Q3 2025, $421397.0 in Q2 2025, and $421397.0 in Q1 2025.